EGFR Mutations and EGFR Tyrosine Kinase Inhibition in Non-Small Cell Lung Cancer

Seminars in Oncology Nursing

Volumn 24, Issue 1, 2008, Pages 27-33

  Miller, Vincent A ^a  

^a NONE

Author keywords

EGFR mutation; Epidermal growth factor receptor (EGFR); erlotinib; gefitinib; kirsten ras (KRAS); oncogene addiction

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; QUINAZOLINE DERIVATIVE;

ARTICLE; DRUG ANTAGONISM; GENETICS; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MUTATION;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; MUTATION; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 38349120527     PISSN: 07492081     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soncn.2007.11.009     Document Type: Article

References (54)

1. Miller V.A., Kris M.G., Shah N., et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 22 (2004) 1103-1109
2. West H., Franklin W.A., Gumerlock P.H., et al. Gefitinib (ZD1839) therapy for advanced bronchioloalveolar lung cancer (BAC): Southwest Oncology Group (SWOG) Study S0126. Proc Am Soc Clin Oncol 22 (2004) 7014 (abstr)
3. Fukuoka M., Yano S., Giaccone G., et al. Multi-Institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21 (2003) 2237-2246
4. Lynch T.J., Bell D.W., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 (2004) 2129-2139
5. Paez J.G., Janne P.A., Lee J.C., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (2004) 1497-1500
6. Pao W., Miller V., Zakowski M., et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101 (2004) 13306-13311
7. Manning G., Whyte D.B., Martinez R., et al. The protein kinase complement of the human genome. Science 298 (2002) 1912-1934
8. Citri A., Skaria K.B., and Yarden Y. The deaf and the dumb: the biology of ErbB-2 and ErbB-3. Exp Cell Res 284 (2003) 54-65
9. Schlessinger J. Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell 110 (2002) 669-672
10. Jorissen R.N., Walker F., Pouliot N., et al. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res 284 (2003) 31-53
11. Yarden Y., and Sliwkowski M.X. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2 (2001) 127-137
12. Miller V., Patel J., Shah N., et al. The epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) shows promising activity in patients with bronchioloalveolar cell carcinoma (BAC): preliminary results of a phase II trial. Proc Am Soc Clin Oncol 22 (2003) 2491 (abstr)
13. Shepherd F.A., Pereira J., Ciuleanu T.E., et al. A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial. Proc Am Soc Clin Onc 22 (2004) 7022 (abstr)
14. Parra H.S., Cavina R., Latteri F., et al. Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer. Br J Cancer 91 (2004) 208-212
15. Sirotnak F.M., Zakowski M.F., Miller V.A., et al. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 6 (2000) 4885-4892
16. Moody S.E., Sarkisian C.J., Hahn K.T., et al. Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. Cancer Cell 2 (2002) 451-461
17. Huettner C.S., Zhang P., Van Etten R.A., et al. Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nat Genet 24 (2000) 57-60
18. Fisher G.H., Wellen S.L., Klimstra D., et al. Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev 15 (2001) 3249-3262
19. Felsher D.W., and Bishop J.M. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell 4 (1999) 199-207
20. Chin L., Tam A., Pomerantz J., et al. Essential role for oncogenic Ras in tumour maintenance. Nature 400 (1999) 468-472
21. Weinstein I. Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science 297 (2002) 63-64
22. Druker B. STI571 (Gleevec) as a paradigm for cancer therapy. Trends Mol Med 8 suppl 4 (2002) S14-S18
23. Demetri G.D. Targeting c-kit mutations in solid tumors; scientific rationale and novel therapeutic options. Semin Oncol 28 (2001) 19-26
24. Cools J., DeAngelo D.J., Gotlib J., et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348 (2003) 1201-1214
25. Bardelli A., Parsons D.W., Silliman N., et al. Mutational analysis of the tyrosine kinome in colorectal cancers. Science 304 (2004) 1164-1166
26. Pao W., and Miller V.A. EGFR mutations, small molecule kinase inhibitors, and non-small cell lung cancer: current knowledge and future directions. J Clin Oncol 23 (2005) 2556-2568
27. Lee J.W., Soung Y.H., Kim S.Y., et al. Absence of EGFR mutation in the kinase domain in common human cancers besides non-small cell lung cancer. Int J Cancer 113 (2004) 510-511
28. Honegger A.M., Dull T.J., Felder S., et al. Point mutation at the ATP binding site of EGF receptor abolishes protein-tyrosine kinase activity and alters cellular routing. Cell 51 (1987) 199-209
29. Huse M., and Kuriyan J. The conformational plasticity of protein kinases. Cell 109 (2002) 275-282
30. Greulich H., Chen T.H., Feng W., et al. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med 2 (2005) e313
31. Riely G.J., Politi K.A., Miller V.A., et al. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res 12 (2006) 7232-7241
32. Thatcher N., Chang A., Parikh P., et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomized, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366 (2005) 1527-1537
33. Shigematsu H., Takahashi T., Nomura M., et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res 65 (2005) 1642-1646
34. Eberhard D.A., Johnson B.E., Amler L.C., et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 23 (2005) 5900-5909
35. Pao W., Wang T.Y., Riely G.J., et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2 (2005) e17
36. Miller V.A., Zakowski M., Riely G.J., et al. EGFR mutation and copy number, EGFR protein expression and KRAS mutation as predictors of outcome with erlotinib in bronchioloalveolar cell carcinoma (BAC): results of a prospective phase II trial. J Clin Oncol 24 (2006) 18S (abstr 7003)
37. Tracy S., Mukohara T., Hansen M., et al. Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255. Cancer Res 64 (2004) 7241-7244
38. Cappuzzo F., Hirsch F.R., Rossi E., et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97 (2005) 643-655
39. Tsao M.S., Sakurada A., Lorimer J., et al. Molecular analysis of the epidermal growth factor receptor (EGFR) gene and protein expression in patients treated with erlotinib in National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial BR.21. J Clin Oncol 23 16S (2005) (abstr 7007)
40. Inoue A., Suzuki T., Fukuhara T., et al. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 24 (2006) 3340-3346
41. Morikawa A., Inoue A., Suzuki T., et al. Prospective analysis of the epidermal growth factor receptor gene mutations in non-small cell lung cancer in Japan. J Clin Oncol 24 18S (2006) (abstr 7077)
42. Paz-Ares L., Sanchez J.M., Garcia-Velasco A., et al. A prospective phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR). J Clin Oncol (2006) 18S (abstr 7020)
43. Sunaga N., Yanagitani N., Kaira K., et al. Phase II study of the efficacy of gefitinib in patients with non-small cell lung cancer with the EGFR mutations. J Clin Oncol 24 (2006) 18S (abstr 7183)
44. Sutani A., Nagai Y., Udagawa K., et al. Phase II study of gefitinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) gene mutations detected by PNA-LNA PCR clamp. J Clin Oncol 24 (2006) 18S (abstr 7076)
45. Asahina H., Yamazaki K., Kinoshita I., et al. A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Br J Cancer 95 (2006) 998-1004
46. Sequist L.V., Martins R.G., Spigel D., et al. iTARGET: A phase II trial to assess the response to gefitinib in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) tumors. J Clin Oncol 25 (2007) 18S (abstr 7504)
47. Shigematsu H., Lin L., Takahashi T., et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97 (2005) 339-346
48. Reed J. Apoptosis and cancer: strategies for integrating programmed cell death. Semin Hematol 37 (2000) 9-16
49. Engelman J.A., Mukohara T., Zejnullahu K., et al. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J Clin Invest 116 (2006) 2695-2706
50. Pan Q., Pao W., and Ladanyi M. Rapid PCR-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas. J Mol Diagn 7 (2005) 396-403
51. Janne P.A., Borras A.M., Kuang Y., et al. A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening. Clin Cancer Res 12 (2006) 751-758
52. Marchetti A., Martella C., Felicioni L., et al. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 23 (2005) 857-865
53. Endo K., Konishi A., Sasaki H., et al. Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay. Lung Cancer 50 (2005) 375-384
54. Pan Q., Pao W., and Ladanyi M. Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas. J Mol Diagn 7 (2005) 396-403